NextCure (NXTC)
(Real Time Quote from BATS)
$1.54 USD
-0.07 (-4.35%)
Updated Aug 27, 2024 02:34 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for NextCure, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 22 | 6 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 22 | 6 |
Selling & Adminstrative & Depr. & Amort Expenses | 68 | 76 | 71 | 64 | 44 |
Income After Depreciation & Amortization | -68 | -76 | -71 | -41 | -37 |
Non-Operating Income | 5 | 1 | 1 | 5 | 4 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -63 | -75 | -69 | -37 | -34 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -63 | -75 | -69 | -37 | -34 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -63 | -75 | -69 | -37 | -34 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -65 | -69 | -64 | -38 | -35 |
Depreciation & Amortization (Cash Flow) | 3 | 7 | 7 | 3 | 3 |
Income After Depreciation & Amortization | -68 | -76 | -71 | -41 | -37 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 27.84 | 27.74 | 27.62 | 27.53 | 15.70 |
Diluted EPS Before Non-Recurring Items | -2.25 | -2.69 | -2.51 | -1.33 | -2.15 |
Diluted Net EPS (GAAP) | -2.25 | -2.69 | -2.51 | -1.33 | -2.15 |
Fiscal Year end for NextCure, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 16.50 | 18.31 | 15.79 | 15.62 | 19.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | -16.50 | -18.31 | -15.79 | -15.62 | -19.16 |
Non-Operating Income | 1.09 | 1.20 | 1.32 | 1.32 | 1.30 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -15.40 | -17.11 | -14.47 | -14.30 | -17.86 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -15.40 | -17.11 | -14.47 | -14.30 | -17.86 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -15.40 | -17.11 | -14.47 | -14.30 | -17.86 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 27.97 | 27.90 | 27.91 | 27.84 | 27.83 |
Diluted EPS Before Non-Recurring Items | -0.55 | -0.61 | -0.52 | -0.51 | -0.64 |
Diluted Net EPS (GAAP) | -0.55 | -0.61 | -0.52 | -0.51 | -0.64 |